Abstract P3-07-04: A multicenter, single-arm, open-label Phase I study of AN1004 (Pelareorep) oncolytic virus plus paclitaxel in Chinese patients with Hormone receptor-positive and HER2-negative advanced/metastatic breast cancer (REO 026-1)
Bibliographic record
Abstract
Abstract A multicenter, single-arm, open-label Phase I study of AN1004 (Pelareorep) oncolytic virus plus paclitaxel in Chinese patients with Hormone receptor-positive and HER2-negative advanced/metastatic breast cancer (REO 026-1) Background: AN1004, also known as Pelareorep is an intravenously delivered immuno-oncolytic unmodified reovirus being evaluated to treat multiple malignancies. AN1004 was shown to be safe and well-tolerated in both monotherapy and combination therapy in multiple clinical trials in North American and European populations, including two completed and two ongoing breast cancer studies. The completed phase 2 study (NCT01656538) in advanced/metastatic breast cancer demonstrated improved median overall survival (OS) in Canadian patients treated with AN1004 plus paclitaxel (PTX) versus PTX alone, and the greatest benefit in OS was observed in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) subtype. Since there has been no clinical trial assessing AN1004 in Chinese population, a bridging study (REO 026-1) was initiated to evaluate its safety and tolerability in combination with PTX in Chinese patients with HR+/HER2- advanced/metastatic breast cancer. Methods: Eligible Chinese patients must be female with good performance status (ECOG PS: 0 or 1), have had histopathological diagnosis with HR+/HER2- advanced/metastatic breast cancer, and were previously treated with at least one endocrine therapy with no more than one line of chemotherapy regimen for recurrent/metastatic disease. Patients are intravenously infused with AN1004 at escalating dose levels of 1.5 × 10^10 (Dose Level 1, DL1 group), 3 × 10^10 (DL2 group) and 4.5 × 10^10 TCID50 (DL3 group) on days 1, 2, 8, 9, 15, and 16 every 28 days plus PTX 80 mg/m^2 intravenously on days 1, 8, and 15 every 28 days. Three to six patients will be enrolled in the DL1 group, and 6 patients will be enrolled in each of the DL2 and DL3 groups. The primary objective is to assess the safety and tolerability of AN1004 in combination with PTX. A secondary objective is to evaluate the preliminary activity of AN1004 and PTX combination therapy. Results: By the data cutoff date of June 2nd, 2022, a total of 10 female patients were enrolled, with a median age of 58 years (range 36-67). Two (20%) patients had failed more than one prior line of endocrine therapy for advanced/metastatic disease, and 3 (30%) patients were previously treated with a CDK4/6 inhibitor. Three patients were treated with AN1004 and PTX in DL1 group; six patients were treated in DL2 group; one patient was treated in DL3 group. The most common (>50%, and/or liver function related) treatment emergent adverse events (TEAEs) included neutrophil count decreased and white blood cell count decreased (90% each), hypertriglyceridemia (70%), pyrexia, ALT increased and anemia (60% each), and AST increased (40%). Three (30%) patients had Grade 3 or above TEAEs, including neutrophil count decreased (30%), white blood cell count decreased (20%), hypertriglyceridemia, ALT increased and GGT increased (10% each). No serious AE or AE leading to treatment discontinuation was reported to date. One patient was not evaluable for dose-limiting toxicity (DLT) due to early withdrawal, and there were no DLTs observed in the 9 evaluable patients. Among the 10 treated patients, 2 (20%) patients achieved confirmed partial response (PR), 2 (20%) patients achieved unconfirmed PR, and 5 (50%) patients showed stable disease (SD). One patient in DL1 group achieved a confirmed PR and later progressed, and the other 8 patients who had PR or SD continue to receive treatment as of the data cut. Conclusion: To date, intravenous administration of AN1004 plus PTX is safe and well-tolerated in Chinese patients with advanced/metastatic breast cancer, and demonstrates anti-tumor activity. Citation Format: Wei Li, Yongmei Yin, Jiuwei Cui, Wenna Wang, Yan Liang, Hongming Liang, Binghe Xu. A multicenter, single-arm, open-label Phase I study of AN1004 (Pelareorep) oncolytic virus plus paclitaxel in Chinese patients with Hormone receptor-positive and HER2-negative advanced/metastatic breast cancer (REO 026-1) [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P3-07-04.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.001 |
| Meta-epidemiology (narrow) | 0.002 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.003 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".